Cargando…

Nephrotoxicity Evaluation on Cisplatin Combined with 5-HT(3) Receptor Antagonists: A Retrospective Study

OBJECTIVE: 5-HT(3) receptor antagonist (ondansetron) has been reported to have nephrotoxic effect when combined with cisplatin in mice; however, little evidence exists in explaining its nephrotoxic effects on patients. The aim of this present study was to investigate whether 5-HT(3) receptor antagon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kou, Wen, Qin, Hongyan, Hanif, Shahbaz, Wu, Xinan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998195/ https://www.ncbi.nlm.nih.gov/pubmed/29977907 http://dx.doi.org/10.1155/2018/1024324

Ejemplares similares

Effects of 5‐HT(₃) receptor antagonists on cisplatin‐induced kidney injury
por: Goda, Mitsuhiro, et al.
Publicado: (2021)

Role of endothelin receptor antagonist; bosentan in cisplatin-induced nephrotoxicity in ovariectomized estradiol treated rats
por: Zahedi, Alieh, et al.
Publicado: (2015)

Azologization of serotonin 5-HT(3) receptor antagonists
por: Rustler, Karin, et al.
Publicado: (2019)

The muscarinic antagonists scopolamine and atropine are competitive antagonists at 5-HT(3) receptors
por: Lochner, Martin, et al.
Publicado: (2016)

Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT(3) receptor antagonists
por: Percie du Sert, N., et al.
Publicado: (2010)

Mechanisms of Cisplatin Nephrotoxicity
por: Miller, Ronald P., et al.
Publicado: (2010)

Prevention of cisplatin nephrotoxicity
por: Hayati, Fatemeh, et al.
Publicado: (2015)

Co-administration of 5-HT6 receptor antagonists with clozapine, risperidone, and a 5-HT2A receptor antagonist: effects on prepulse inhibition in rats
por: Fijał, Katarzyna, et al.
Publicado: (2013)

Evaluating dose of cisplatin responsible for causing nephrotoxicity
por: Higuchi, Kyouko, et al.
Publicado: (2019)

Constitutively Active 5-HT Receptors: An Explanation of How 5-HT Antagonists Inhibit Gut Motility in Species Where 5-HT is Not an Enteric Neurotransmitter?
por: Spencer, Nick J.
Publicado: (2015)

Role of 5-HT(2A) receptor antagonists in the treatment of insomnia
por: Vanover, Kimberly E, et al.
Publicado: (2010)

Extended N-Arylsulfonylindoles as 5-HT(6) Receptor Antagonists: Design, Synthesis & Biological Evaluation
por: Vera, Gonzalo, et al.
Publicado: (2016)

Existence of Brain 5-HT1A–5-HT2A Isoreceptor Complexes with Antagonistic Allosteric Receptor–Receptor Interactions Regulating 5-HT1A Receptor Recognition
por: Borroto-Escuela, Dasiel O., et al.
Publicado: (2017)

Role of endothelin-1 antagonist; bosentan, against cisplatin-induced nephrotoxicity in male and female rats
por: Jokar, Zahra, et al.
Publicado: (2015)

Reduction of the serotonin 5-HT(1B) and 5-HT(2A) receptor-mediated contraction of human pulmonary artery by the combined 5-HT(1B) receptor antagonist and serotonin transporter inhibitor LY393558
por: Baranowska-Kuczko, Marta, et al.
Publicado: (2020)

Renin-angiotensin system inhibitors combined with cisplatin exacerbate cisplatin-induced nephrotoxicity in mice
por: Tsuji, Takumi, et al.
Publicado: (2022)

5-HT1A agonists, 5-HT3 antagonists and benzodiazepines : their comparative behavioural pharmacology /
Publicado: (1991)

CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine
por: Capi, Matilde, et al.
Publicado: (2021)

Agonists and antagonists induce different palonosetron dissociation rates in 5-HT(3)A and 5-HT(3)AB receptors()
por: Lummis, Sarah C.R., et al.
Publicado: (2013)

Impact of 5-HT(3) receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study
por: Lin, Swu-Jane, et al.
Publicado: (2012)

Autophagy in Cisplatin Nephrotoxicity during Cancer Therapy
por: Hu, Xiaoru, et al.
Publicado: (2021)

Distribution of cells responsive to 5-HT(6) receptor antagonist-induced hypophagia
por: Garfield, Alastair S., et al.
Publicado: (2014)

Recent advances in antiemetics: new formulations of 5HT(3)-receptor antagonists
por: Gilmore, James, et al.
Publicado: (2018)

Serotonin 5-HT3 Receptor Antagonist for Treatment of Severe Diabetic Diarrhea
por: Murao, Satoshi, et al.
Publicado: (2010)

Correction: Synthesis and evaluation of nuciferine and roemerine enantiomers as 5-HT(2) and α(1) receptor antagonists
por: Heng, Hui Li, et al.
Publicado: (2018)

Aging increases the susceptibility of cisplatin-induced nephrotoxicity
por: Wen, Jiagen, et al.
Publicado: (2015)

Natural products: potential treatments for cisplatin-induced nephrotoxicity
por: Fang, Chun-yan, et al.
Publicado: (2021)

Amelioration of cisplatin-induced nephrotoxicity by statins
por: Maheshwari, Rajesh A., et al.
Publicado: (2013)

5-HT3 receptor antagonists for the prevention of postoperative shivering: a meta-analysis
por: Zhou, Chengmao, et al.
Publicado: (2016)

Dual 5-HT(3) and 5-HT(6) Receptor Antagonist FPPQ Normalizes Phencyclidine-Induced Disruption of Brain Oscillatory Activity in Rats
por: Castañé, Anna, et al.
Publicado: (2022)

Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study
por: Komaki, Kazumi, et al.
Publicado: (2017)

5-HT3 and 5-HT4 antagonists inhibit peristaltic contractions in guinea-pig distal colon by mechanisms independent of endogenous 5-HT
por: Sia, Tiong C., et al.
Publicado: (2013)

The 5-HT(2C) receptor agonist, lorcaserin, and the 5-HT(6) receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour
por: Higgs, Suzanne, et al.
Publicado: (2015)

The evaluation of urinary calprotectin levels for prediction of acute cisplatin-induced nephrotoxicity
por: Koçak, Gülay, et al.
Publicado: (2022)

Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors
por: Sato, Ko, et al.
Publicado: (2016)

[6]-Gingerol Ameliorates Cisplatin-Induced Pica by Regulating the TPH/MAO-A/SERT/5-HT/5-HT(3) Receptor System in Rats
por: Cheng, Qianqian, et al.
Publicado: (2020)

Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT(3) and 5-HT(6) Receptor Antagonist with Antipsychotic and Procognitive Properties
por: Zajdel, Paweł, et al.
Publicado: (2021)

Effect of infliximab against cisplatin-induced nephrotoxicity
por: Cure, Erkan, et al.
Publicado: (2014)

Renoprotective effects of antioxidants against cisplatin nephrotoxicity
por: Hajian, Shabnam, et al.
Publicado: (2014)

Cisplatin therapy and the problem of gender-related nephrotoxicity
por: Nasri, Hamid
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_iqu4qeitf57c89kg5c1nfodvna